Orforglipron vs Ozempic: Head-to-Head Results

Written by the GLP-1 Coach editorial team. Last updated August 12, 2026.

If you've been searching "orforglipron vs Ozempic" over the past few months, you're not imagining the noise — the head-to-head trial data landed, orforglipron got FDA approval in April 2026 (under the brand name Foundayo), and it's the first oral GLP-1 pill that doesn't need to be taken with food or water restrictions. It's the biggest structural change to the GLP-1 landscape since Mounjaro launched.

Here's what the data actually shows, and — more usefully for anyone reading this site — what an oral GLP-1 changes (and doesn't change) for the muscle-preservation side of the equation.

What is orforglipron, and where does it stand right now?

Orforglipron is a once-daily oral GLP-1 receptor agonist from Eli Lilly. Unlike semaglutide (which is a peptide and requires either weekly injection as Ozempic/Wegovy, or a strict fasting-window pill as Rybelsus), orforglipron is a small-molecule non-peptide — it survives digestion, so it can be swallowed like any other tablet, any time of day.

The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity or overweight plus a weight-related condition. It's sold as Foundayo, initially through LillyDirect and rolling out to pharmacies and telehealth from there.

What did the head-to-head trial actually show?

The comparison people are actually searching for is the ACHIEVE-3 trial — a 52-week Phase 3 study in adults with type 2 diabetes that put orforglipron directly against oral semaglutide (the Rybelsus formulation of Ozempic's active ingredient).

At the highest doses:

Metric	Orforglipron 36 mg	Oral semaglutide 14 mg
Average weight loss	9.2% (~19.7 lbs)	5.3% (~11.0 lbs)
A1C reduction	2.2%	1.4%
Treatment discontinuation from side effects	8.7%–9.7%	4.5%–4.9%

That's roughly 74% more weight loss on orforglipron at the top dose. In the separate ATTAIN-1 obesity trial (published in the New England Journal of Medicine), orforglipron 36 mg produced an average weight loss of 12.4% (about 27.3 lbs) at 72 weeks, versus 2.1% on placebo.

For context, injectable semaglutide (Wegovy) has historically produced around 15% average weight loss at 68 weeks in its pivotal trials — so orforglipron lands somewhere in between oral semaglutide and injectable semaglutide on efficacy, closer to the injectable side.

Oral vs injectable — what actually changes for you?

The convenience story is obvious — a daily pill you don't have to refrigerate, don't have to inject, and can take with or without food is a real usability improvement. But that's the part most of the coverage focuses on, and it's not the part that matters most if you're reading this site.

The parts that matter for muscle preservation are: how hard is it to eat while on it, and what happens to lean mass.

Does orforglipron cause less nausea than injectable Ozempic?

This is where oral vs injectable does not let you off the hook.

In ATTAIN-1, GI side effects on orforglipron came in at rates broadly similar to injectable GLP-1s:

• Nausea: 28.9%–35.9% across the three doses, vs 10.4% on placebo
• Constipation: 21.7%–29.8% vs 9.3%
• Diarrhea: 21.0%–23.1% vs 9.6%
• Vomiting: 13.0%–24.0% vs 3.5%

Treatment discontinuation from side effects rose with dose — 5.3% at 6 mg, 7.9% at 12 mg, 10.3% at 36 mg. In the head-to-head against oral semaglutide (ACHIEVE-3), orforglipron's discontinuation rate was somewhat higher (8.7%–9.7% vs 4.5%–4.9%).

The practical takeaway: switching from an injectable to a pill does not appear to blunt the appetite suppression or the nausea window. If anything, at the higher doses used for meaningful weight loss, orforglipron's GI profile looks comparable to — not milder than — injectable semaglutide. That means the same core problem this site keeps pointing at applies: when appetite is suppressed hard enough to drive real weight loss, protein intake is the first thing that drops, and that's true whether the drug entered your body through a needle or your mouth. Use the protein calculator to establish a daily target before hunger suppression makes hitting it harder.

What does the lean mass data actually look like?

The one number worth pulling out of the orforglipron data specifically: in the pooled DEXA body composition subgroup, participants lost an average of 13.8% fat mass, 19% visceral fat mass — and 4.5% lean mass.

That 4.5% lean mass loss is in line with what's been reported for injectable GLP-1s in similar studies — the broader context is covered in muscle loss after stopping GLP-1s: why you likely regain fat, not muscle. In other words: the oral formulation doesn't appear to be more (or less) muscle-sparing than the injectable version. The mechanism that drives fat loss — sustained calorie deficit through appetite suppression — is the same one that puts lean mass at risk if protein and resistance activity aren't deliberately in place. If the scale stalls during treatment, the muscle-loss-in-disguise plateau guide explains how to tell whether inadequate protein is the culprit.

What if I'm already on Ozempic — should I switch?

A few things worth being clear about:

• Orforglipron's efficacy sits between oral semaglutide and injectable semaglutide/Wegovy — it's genuinely competitive, not a compromise pill.
• The side effect profile is roughly comparable to injectable GLP-1s. Don't expect the pill to be gentler.
• The muscle-preservation math doesn't change based on delivery route. Protein target, resistance activity, and consistent tracking matter just as much on an oral GLP-1 as they do on an injectable.
• The ATTAIN-MAINTAIN trial specifically looked at people transitioning off Wegovy or Zepbound onto orforglipron for weight maintenance — and it worked, with participants retaining about 74.7% of their prior weight loss on orforglipron vs 49.2% on placebo. So there's now a real oral option for the maintenance phase, which is arguably the highest-stakes stretch of any GLP-1 journey.

Whether the pill is the right fit versus staying on an injectable is a prescriber conversation, not a headline question. The efficacy is real; the trade-offs mostly aren't in the places the marketing focuses on.

The bottom line

Bottom line: Orforglipron is real, effective, and more convenient — but it's not a gentler drug. Nausea, appetite suppression, and lean mass loss look comparable to injectable GLP-1s. The muscle-preservation work (protein target, resistance activity, tracking) is exactly the same whether you're on a pill or a shot.

Final Thoughts

Whether orforglipron or Ozempic is "the right one" depends far more on your specific situation than on the drug names themselves. If needle avoidance, flexible dosing, or a maintenance-phase option is what's blocking adherence for you, an oral GLP-1 is a genuinely useful addition to the landscape. If you're already tolerating an injectable well and it's producing the results you want, there's no urgent reason to switch — the efficacy delta at maintenance doses is meaningful but not dramatic.

What doesn't change either way: the muscle-preservation math. The drug creates the deficit; your protein intake and resistance activity determine what you lose. The muscle preservation guide covers resistance training and protein timing in detail. The tools on this site — weekly protein tracking, dose-change awareness, week-by-week pattern spotting — are built to support the habit side of that equation, not to replace the medical decisions that belong with your prescriber.

---

Related:

• Is Your Weight-Loss Plateau Actually Muscle Loss in Disguise?
• Muscle Loss After Stopping GLP-1s: Why You Likely Regain Fat, Not Muscle
• Muscle Preservation Guide

---

This article is educational and not a substitute for medical advice. Orforglipron (Foundayo) is a prescription medication — decisions about starting, switching, or stopping any GLP-1 therapy should always be made with your prescriber.

Sources: Eli Lilly press release, ATTAIN-1 NEJM results; ACHIEVE-3 head-to-head vs oral semaglutide, published in The Lancet; ATTAIN-MAINTAIN trial, Nature Medicine; FDA approval announcement, April 2026.